Mykhaylo Korda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mykhaylo Korda has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Anatoliy Anchev
International Humanitarian University, Odesa, Ukraine
1 shared publication- Anatoliy Gozhenko
State Enterprise "Ukrainian Research Institute for Transport Medicine", Ministry of Health of Ukraine, Odesa, Ukraine
1 shared publication - Andriy Nykyforuk
Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine
1 shared publication - Dariya Popovych
IY Horbachevskyi National Medical University, Ternopil’, UKRAINE
1 shared publication - Igor Bombushkar
Ukrainian Scientific Research Institute of Medicine of Transport, Odesa, Ukraine
1 shared publication - Igor Popovych
Bohomolets’ Institute of Physiology of NAS, Kyїv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 1 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60626
Phytotea “ATINE” enhances the immunomodulatory effect of adaptogenic factors of the Truskavets’ Spa in patients after radical treatment of oncological pathology
Background. The beneficial effect of balneofactors of the Truskavets’ Spa on the immune status of patients with various chronic diseases is well known. On the other hand, a similar immunomodulatory effect is exerted by various medicinal plants. Based on this, we set ourselves the goal of clarifying the possibility of enhancing the immunotropic effect of balneofactors by combining them with medicinal plants. Material and methods. The subjects of the study were 52 patients aged 44÷75 years (36 women aged 59.3±9.3 years and 16 men aged 60.0±8.3 years), who came for rehabilitation at the Truskavets' Spa after radical treatment of oncopathology. The state of cellular, humoral and phagocytic links of immunity was assessed using routine methods, and two equal groups were formed on this basis. Members of the control group received standard balneotherapy for two weeks, while the main group additionally consumed the newly created herbal tea “ATINE”. Results. Supplementing standard balneotherapy with phytotea “ATINE” significantly modulated its immunotropic effects. First, “ATINE” neutralized the balneotherapy-induced decrease in IgG levels, reversed the tendency to decrease neutrophils content into an increasing trend, initiated an increase in CIC and T-killer levels, as well as enhanced the activating effect of balneotherapy on the level of natural killer cells. Secondly, “ATINE” leveled the balneotherapy-induced increase in the absolute content of B-lymphocytes and IgA in the blood, initiated a decrease in the absolute content of pan-lymphocytes and T-helpers, and deepened the balneotherapy-induced decrease in the relative content of T-helpers and IgM. However, the additional use of “ATINE” did not affect the balneotherapy-induced increase in the bactericidal ability of blood neutrophils and its factors (activity, intensity and completeness of phagocytosis of the Staph. aureus strain), the absolute content of natural killers and the relative content of B-lymphocytes, the reaction of blast transformation of T-lymphocytes to PHA, as well as the entropy of the immunocytogram. Conclusion. Phytotea “ATINE” enhances the immunomodulatory effect of adaptogenic factors of the Truskavets’ spa in patients after radical treatment of oncological pathology. Based on the analysis of the research document on "ATINE" herbal tea used in patients after radical oncological treatment at the Truskavets Spa, the following conclusions supported by mathematical analysis can be drawn. 1. "ATINE" herbal tea significantly increases NK and T-killer cell levels. Mathematical confirmation: NK cell level increase: standard balneotherapy effect was +0.51±0.09 (p<0.05), while with additional "ATINE" it increased to +0.97±0.10 (p<0.05); "ATINE" effect alone: +0.46±0.10; T-killer level increase: standard balneotherapy +0.05±0.56 (non-significant), with "ATINE" +1.36±0.46 (p<0.05); "ATINE" effect alone on T-killers: +1.31±0.51; Discriminant analysis confirmed these effects with r*=0.654; Wilks' Λ=0.547; χ²(12)=60; p<10⁻⁶. 2. "ATINE" modulates immune response by decreasing T-helper and IgM levels. Mathematical confirmation: T-helper level decrease: standard balneotherapy -0.54±0.28 (non-significant), with "ATINE" -1.16±0.23 (p<0.05); "ATINE" effect alone on T-helpers: -0.62±0.26; IgM level decrease: standard balneotherapy -1.47±0.28 (p<0.05), with "ATINE" -2.59±0.44 (p<0.05); "ATINE" effect alone on IgM: -1.12±0.36; Regression analysis showed strong correlation between T-killer and T-helper level changes: R=0.909; R²=0.826; p<10⁻⁶. 3. "ATINE" increases circulating immune complexes (CIC) without affecting neutrophil bactericidal capacity. Mathematical confirmation: CIC level change: standard balneotherapy -0.12±0.30 (non-significant), with "ATINE" +0.77±0.34 (p<0.05); "ATINE" effect alone on CIC: +0.89±0.32; No difference in neutrophil bactericidal capacity (BCCN): standard balneotherapy +1.10±0.58, with "ATINE" +1.06±0.35 (p<0.05); t-value for effect comparison: 0.00 (complete absence of difference); Mahalanobis distances between groups confirm significant differences between baseline and both therapies (p<10⁻⁶), as well as between standard balneotherapy and therapy with "ATINE" (p=0.075).
- 1 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60626
Open AccessPhytotea “ATINE” enhances the immunomodulatory effect of adaptogenic factors of the Truskavets’ Spa in patients after radical treatment of oncological pathology
Background. The beneficial effect of balneofactors of the Truskavets’ Spa on the immune status of patients with various chronic diseases is well known. On the other hand, a similar immunomodulatory effect is exerted by various medicinal plants. Based on this, we set ourselves the goal of clarifying the possibility of enhancing the immunotropic effect of balneofactors by combining them with medicinal plants. Material and methods. The subjects of the study were 52 patients aged 44÷75 years (36 women aged 59.3±9.3 years and 16 men aged 60.0±8.3 years), who came for rehabilitation at the Truskavets' Spa after radical treatment of oncopathology. The state of cellular, humoral and phagocytic links of immunity was assessed using routine methods, and two equal groups were formed on this basis. Members of the control group received standard balneotherapy for two weeks, while the main group additionally consumed the newly created herbal tea “ATINE”. Results. Supplementing standard balneotherapy with phytotea “ATINE” significantly modulated its immunotropic effects. First, “ATINE” neutralized the balneotherapy-induced decrease in IgG levels, reversed the tendency to decrease neutrophils content into an increasing trend, initiated an increase in CIC and T-killer levels, as well as enhanced the activating effect of balneotherapy on the level of natural killer cells. Secondly, “ATINE” leveled the balneotherapy-induced increase in the absolute content of B-lymphocytes and IgA in the blood, initiated a decrease in the absolute content of pan-lymphocytes and T-helpers, and deepened the balneotherapy-induced decrease in the relative content of T-helpers and IgM. However, the additional use of “ATINE” did not affect the balneotherapy-induced increase in the bactericidal ability of blood neutrophils and its factors (activity, intensity and completeness of phagocytosis of the Staph. aureus strain), the absolute content of natural killers and the relative content of B-lymphocytes, the reaction of blast transformation of T-lymphocytes to PHA, as well as the entropy of the immunocytogram. Conclusion. Phytotea “ATINE” enhances the immunomodulatory effect of adaptogenic factors of the Truskavets’ spa in patients after radical treatment of oncological pathology. Based on the analysis of the research document on "ATINE" herbal tea used in patients after radical oncological treatment at the Truskavets Spa, the following conclusions supported by mathematical analysis can be drawn. 1. "ATINE" herbal tea significantly increases NK and T-killer cell levels. Mathematical confirmation: NK cell level increase: standard balneotherapy effect was +0.51±0.09 (p<0.05), while with additional "ATINE" it increased to +0.97±0.10 (p<0.05); "ATINE" effect alone: +0.46±0.10; T-killer level increase: standard balneotherapy +0.05±0.56 (non-significant), with "ATINE" +1.36±0.46 (p<0.05); "ATINE" effect alone on T-killers: +1.31±0.51; Discriminant analysis confirmed these effects with r*=0.654; Wilks' Λ=0.547; χ²(12)=60; p<10⁻⁶. 2. "ATINE" modulates immune response by decreasing T-helper and IgM levels. Mathematical confirmation: T-helper level decrease: standard balneotherapy -0.54±0.28 (non-significant), with "ATINE" -1.16±0.23 (p<0.05); "ATINE" effect alone on T-helpers: -0.62±0.26; IgM level decrease: standard balneotherapy -1.47±0.28 (p<0.05), with "ATINE" -2.59±0.44 (p<0.05); "ATINE" effect alone on IgM: -1.12±0.36; Regression analysis showed strong correlation between T-killer and T-helper level changes: R=0.909; R²=0.826; p<10⁻⁶. 3. "ATINE" increases circulating immune complexes (CIC) without affecting neutrophil bactericidal capacity. Mathematical confirmation: CIC level change: standard balneotherapy -0.12±0.30 (non-significant), with "ATINE" +0.77±0.34 (p<0.05); "ATINE" effect alone on CIC: +0.89±0.32; No difference in neutrophil bactericidal capacity (BCCN): standard balneotherapy +1.10±0.58, with "ATINE" +1.06±0.35 (p<0.05); t-value for effect comparison: 0.00 (complete absence of difference); Mahalanobis distances between groups confirm significant differences between baseline and both therapies (p<10⁻⁶), as well as between standard balneotherapy and therapy with "ATINE" (p=0.075).
- Open Access
Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword
Coronavirus disease 2019, or COVID-19, is a major challenge facing scientists worldwide. Alongside the lungs, the system of organs comprising the GI tract is commonly targeted by COVID-19. The dysbiotic modulations in the intestine influence the disease severity, potentially due to the ability of the intestinal microbiota to modulate T lymphocyte functions, i.e., to suppress or activate T cell subpopulations. The interplay between the lungs and intestinal microbiota is named the gut–lung axis. One of the most usual comorbidities in COVID-19 patients is type 2 diabetes, which induces changes in intestinal microbiota, resulting in a pro-inflammatory immune response, and consequently, a more severe course of COVID-19. However, changes in the microbiota in this comorbid pathology remain unclear. Metformin is used as a medication to treat type 2 diabetes. The use of the type 2 diabetes drug metformin is a promising treatment for this comorbidity because, in addition to its hypoglycemic action, it can increase amount of intestinal bacteria that induce regulatory T cell response. This dual activity of metformin can reduce lung damage and improve the course of the COVID-19 disease.
Open AccessImmunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword
Coronavirus disease 2019, or COVID-19, is a major challenge facing scientists worldwide. Alongside the lungs, the system of organs comprising the GI tract is commonly targeted by COVID-19. The dysbiotic modulations in the intestine influence the disease severity, potentially due to the ability of the intestinal microbiota to modulate T lymphocyte functions, i.e., to suppress or activate T cell subpopulations. The interplay between the lungs and intestinal microbiota is named the gut–lung axis. One of the most usual comorbidities in COVID-19 patients is type 2 diabetes, which induces changes in intestinal microbiota, resulting in a pro-inflammatory immune response, and consequently, a more severe course of COVID-19. However, changes in the microbiota in this comorbid pathology remain unclear. Metformin is used as a medication to treat type 2 diabetes. The use of the type 2 diabetes drug metformin is a promising treatment for this comorbidity because, in addition to its hypoglycemic action, it can increase amount of intestinal bacteria that induce regulatory T cell response. This dual activity of metformin can reduce lung damage and improve the course of the COVID-19 disease.